Merck gets positive EU CHMP opinion for KEYTRUDA plus Padcev in bladder cancer
Merck said the EU CHMP adopted a positive opinion recommending approval of KEYTRUDA (pembrolizumab) with Padcev (enfortumab vedotin) as perioperative treatment for adults with resectable muscle-invasive bladder cancer.